Viemed Healthcare Inc

Viemed Healthcare, a provider of home-based respiratory therapy, outlined its growth strategy at the Midwest IDEAS Conference, projecting low-20% revenue growth in 2026 with approximately $317 million in revenue and $66 million in EBITDA. The company sees a large untapped market: only about 60,000 beneficiaries currently receive its ventilation therapy, versus an estimated 1.25 million Medicare-eligible potential patients. CEO Casey Hoyt noted that complex respiratory services account for roughly half of the business, serving more than 198,000 patients nationwide. Growth is supported by expanding sleep-resupply and maternal-health segments, though these lower-margin lines may pressure EBITDA margins. Viemed has completed three acquisitions in three years, including Lehan's for roughly $28 million to $30 million, and maintains a debt-free balance sheet with leverage expected to stay below two times EBITDA for any major deal.

Several biotech stocks reached 52-week highs on July 14, 2026, driven by positive clinical data and new program launches. Hemab Therapeutics hit $42.03 after reporting encouraging Phase 2 results for its Von Willebrand's disease candidate HMB-002 and unveiling a new drug candidate, HMB-003, for heavy menstrual bleeding. Alamar Biosciences touched $29.43 following a partnership with U.S. research universities to launch a national proteomics initiative using its NULISAseq Neuro 220 panel for Alzheimer's biomarker discovery. Progyny rose over 4% to $32, with the company projecting full-year 2026 revenue between $1.365 billion and $1.405 billion, a 5.9% to 9% increase. 10x Genomics closed at a 52-week high of $43.98 after recent collaborations, including a bladder cancer diagnostic project with Cleveland Clinic, and expects 2026 revenue of $600 million to $625 million. Viemed Healthcare peaked at $12.61, forecasting net revenues of $312 million to $320 million for 2026.